Monopar Therapeutics Inc. Share Price

Monopar Therapeutics Inc. Share Price

NASDAQ: MNPR
$71.16
-$0.16 (-0.22%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Monopar Therapeutics Inc. Stock Performance

Open
$73.09
Prev. Close
$71.31
Circuit Range
N/A
Day Range
$70.14 - $73.19
Year Range
$50.33 - $123.95
Volume
4,432
Average Traded
$70.95

Monopar Therapeutics Inc. Share Price Today

As of 18 November 2026, Monopar Therapeutics Inc.'s share price is $71.16. The stock opened at $73.09, compared to its previous close of $71.31. During today's trading session, Monopar Therapeutics Inc.'s share price traded between $70.14 and $73.19, with an average price of $71.66. Over the past 52 weeks, the stock has recorded a high of $123.95 and a low of $50.33. In terms of performance, Monopar Therapeutics Inc.'s share price has risen by 9.89% over the last six months and is down 16.92% on a year-on-year basis.

Monopar Therapeutics Inc. Share Price Chart

Line chart of the Monopar Therapeutics Inc. price trend over the selected period. The price fell overall, ranging from 69.38 to 73.19, ending at 71.16.
$70.14$73.19
L
Show Current Price
H

Monopar Therapeutics Inc. Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.63
Revenue (TTM)
$0.00
Return On Equity (TTM)
-13.64%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-19.23%

Monopar Therapeutics Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$5.20-$3.89-$5.31-$6.20
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A25.19%-36.50%-16.76%

Monopar Therapeutics Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.52-$8.40-$15.59-$13.72
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A20.15%-85.60%11.99%

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Monopar Therapeutics Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$69.00
$71.33
+1.08%
Oct 2026
$79.41
$70.56
-11.36%
Sep 2026
$113.19
$79.60
-30.67%
Aug 2026
$107.40
$114.82
+6.10%
Jul 2026
$95.57
$108.22
+17.05%
Jun 2026
$65.00
$92.46
+42.80%
May 2026
$51.35
$64.75
+22.84%
Apr 2026
$56.07
$52.71
-4.16%
Mar 2026
$53.38
$55.00
+0.25%
Feb 2026
$62.62
$54.87
-9.77%
Jan 2026
$66.06
$60.80
-6.57%
Dec 2025
$82.99
$65.08
-24.01%

MNPR Share Price FAQs